The C.A.M. Report
Complementary and Alternative Medicine: Fair, Balanced, and to the Point
  • About this web log

    This blog is intended as an objective and dispassionate source of information on the latest CAM research. Since my background is in pharmacy and allopathic medicine, I view all CAM as advancing through the development pipeline to eventually become integrated into mainstream medical practice. Some will succeed while others fail. But all are treated fairly here.

  • About the author

    John Russo, Jr., PharmD, is president of The MedCom Resource, Inc. Previously, he was senior vice president of medical communications at www.Vicus.com, a complementary and alternative medicine website.

  • Common sense considerations

    The material on this weblog is for informational purposes. It is not medical advice or counsel. Be smart, consult your health professional before using CAM.

  • Support this site

    If you found the information here helpful, please consider supporting this site.If you found the information here helpful, please consider supporting this site.

  • Recent Posts

  • Recent Comments

    Is there a role for milk thistle treatment of liver toxicity in leukemia?

    Liver-DamageMilk thistle is often used to treat chemotherapy-associated liver toxicity.

    Researchers from the US studied it in childhood acute lymphoblastic leukemia (ALL).

    First, the details.

    • 50 children with ALL and liver toxicity were randomly assigned to a treatment group for 28 days.
      • Milk thistle
      • Placebo
    • Neither the researchers nor patients knew the treatment given — double blind.
    • Liver function tests were evaluated during the study.
    • Also, milk thistle was studied in the laboratory using ALL cells.

    And, the results.

    • There were no significant differences in the frequency of side effects, the incidence and severity of toxicities, or infections between groups.
    • There were no significant changes in the liver enzymes amino alanine transferase (ALT), aspartate amino transferase (AST), or total bilirubin at Day 28.
      • These data suggest no liver toxicity and no obstruction of bile flow.
    • At Day 56, the milk thistle group had a significantly lower AST.
    • There were no significantly different doses of chemotherapy between groups.
    • In laboratory.
      • No antagonistic interactions between milk thistle and the drugs vincristine (Oncovin) or L-asparaginase in human leukemic lymphoblasts cells.
      • Modest synergy with vincristine was observed.

    The bottom line?

    The authors concluded, “Milk thistle was associated with a trend toward significant reductions in liver toxicity. Milk thistle did not antagonize the effects of chemotherapy agents used for the treatment of ALL.”

    The results of earlier studies suggest that milk thistle reduces liver damage caused by cirrhosis or ingested toxins.

    The next step, according to the authors, is to determine the most effective dose and duration of milk thistle therapy and its effect on survival in these patients.

    Actually, the next step should be to guarantee the contents of each tablet in each bottle of milk thistle sole in stores.

    12/27/09 16:11 JR

    Leave a Comment

    XHTML: Line-breaks are automatic. Available tags are <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>